- Home
- THTX vs IGMS Comparison
THTX vs IGMS Comparison
Compare THTX & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- IGMS
- Stock Information
- Founded
- THTX 1993
- IGMS 1993
- Country
- THTX Canada
- IGMS United States
- Employees
- THTX N/A
- IGMS N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- IGMS Health Care
- Exchange
- THTX Nasdaq
- IGMS Nasdaq
- Market Cap
- THTX 71.3M
- IGMS 82.1M
- IPO Year
- THTX N/A
- IGMS 2019
- Fundamental
- Price
- THTX $1.50
- IGMS $1.24
- Analyst Decision
- THTX Hold
- IGMS Hold
- Analyst Count
- THTX 1
- IGMS 8
- Target Price
- THTX N/A
- IGMS $6.14
- AVG Volume (30 Days)
- THTX 2.9M
- IGMS 198.4K
- Earning Date
- THTX 04-09-2025
- IGMS 03-06-2025
- Dividend Yield
- THTX N/A
- IGMS N/A
- EPS Growth
- THTX N/A
- IGMS N/A
- EPS
- THTX N/A
- IGMS N/A
- Revenue
- THTX $85,866,000.00
- IGMS $2,679,000.00
- Revenue This Year
- THTX $3.57
- IGMS $134.71
- Revenue Next Year
- THTX $7.73
- IGMS $74.27
- P/E Ratio
- THTX N/A
- IGMS N/A
- Revenue Growth
- THTX 5.02
- IGMS 25.77
- 52 Week Low
- THTX $1.08
- IGMS $1.15
- 52 Week High
- THTX $2.18
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- THTX 44.19
- IGMS 37.38
- Support Level
- THTX $1.51
- IGMS $1.17
- Resistance Level
- THTX $2.12
- IGMS $1.31
- Average True Range (ATR)
- THTX 0.12
- IGMS 0.09
- MACD
- THTX 0.01
- IGMS 0.05
- Stochastic Oscillator
- THTX 7.46
- IGMS 32.14
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.